Ocugen

Ocugen sniffs out COVID-19 vaccine opportunity, landing rights to nasal candidate with India authorization
Ocugen sniffs out COVID-19 vaccine opportunity, landing rights to nasal candidate with India authorization
Fierce Pharma
Ocugen
vaccines
COVID-19
intranasal vaccines
Europe
Japan
India
Flag link:
Merck, Emergent, Affinivax and Ocugen Level Up in Vaccine Development
Merck, Emergent, Affinivax and Ocugen Level Up in Vaccine Development
BioSpace
Merck
Emergent BioSolutions
Affinivax
Ocugen
vaccines
chikungunya virus
pneumococcal disease
COVID-19
Flag link:
FDA lifts hold on Ocugen's COVID-19 vaccine trial. But is it too late for the shot?
FDA lifts hold on Ocugen's COVID-19 vaccine trial. But is it too late for the shot?
Fierce Pharma
Ocugen
FDA
clinical hold
vaccines
COVID-19
Covaxin
Flag link:
FDA warns small biotech Ocugen of potential $10K fines for failing to post trial results
FDA warns small biotech Ocugen of potential $10K fines for failing to post trial results
Endpoints
FDA
regulatory
clinical trials
Ocugen
vaccines
COVID-19
Flag link:
Vaccine Stocks Are Rising, but This Biotech Is Monday's Big Nasdaq Winner
Vaccine Stocks Are Rising, but This Biotech Is Monday's Big Nasdaq Winner
Motley Fool
biotech stocks
NASDAQ
vaccines
Novavax
Moderna Therapeutics
Ocugen
Intra-Cellular Therapies
Caplyta
Flag link:
Ocugen hits another snag in bringing its Bharat Biotech-partnered Covid-19 vaccine to the US
Ocugen hits another snag in bringing its Bharat Biotech-partnered Covid-19 vaccine to the US
Endpoints
Ocugen
Bharat Biotech
Covaxin
vaccines
COVID-19
Flag link:
Is Ocugen About to Beat Moderna in This One Market?
Is Ocugen About to Beat Moderna in This One Market?
Motley Fool
Moderna Therapeutics
Ocugen
vaccines
Covaxin
COVID-19
pediatric
Flag link:
This Surprising FDA Announcement Could Be Huge for Ocugen
This Surprising FDA Announcement Could Be Huge for Ocugen
Motley Fool
Ocugen
COVID-19
vaccines
Flag link:
2 Biotech Stocks That Could Go Parabolic This Week
2 Biotech Stocks That Could Go Parabolic This Week
Motley Fool
biotech
biotech stocks
Aurinia Pharmaceuticals
M&A
Ocugen
Covaxin
vaccines
COVID-19
Flag link:
Ocugen preps filings for COVID-19 vaccine Covaxin on new data
Ocugen preps filings for COVID-19 vaccine Covaxin on new data
Pharmaforum
Ocugen
COVID-19
vaccines
Covaxin
Flag link:
Ocugen plans to seek full approval for Covaxin in US
Ocugen plans to seek full approval for Covaxin in US
Pharmaceutical Business Review
Ocugen
Covaxin
FDA
vaccines
COVID-19
Flag link:
Ocugen On Track to Bring Bharat Biotech's COVAXIN to US Market With Strong Data
Ocugen On Track to Bring Bharat Biotech's COVAXIN to US Market With Strong Data
BioSpace
Ocugen
COVID-19
vaccines
Bharat Biotech
Flag link:
Valneva joins the phase 3 Covid-19 vaccine club
Valneva joins the phase 3 Covid-19 vaccine club
EP Vantage
Valneva
VLA2001
vaccines
COVID-19
clinical trials
Ocugen
Covaxin
Flag link:
Can COVID Vaccine Latecomer Ocugen Beat Pfizer and Moderna?
Can COVID Vaccine Latecomer Ocugen Beat Pfizer and Moderna?
Motley Fool
vaccines
COVID-19
Ocugen
Bharat Biotech
Flag link:
Battered and out of options, Histogenics turns to eye drug developer Ocugen for reverse merger
Battered and out of options, Histogenics turns to eye drug developer Ocugen for reverse merger
Endpoints
Histogenics
Ocugen
M&A
Flag link:
Ocugen’s Dry Eye Disease Therapy Could Compete with Allergan and Shire
Ocugen’s Dry Eye Disease Therapy Could Compete with Allergan and Shire
Xtalks
Ocugen
dry eye disease
OCU310
Shire
Allergan
Restasis
Xiidra
Flag link:
How this biotech plans to go up against big pharma with its eye disease products
How this biotech plans to go up against big pharma with its eye disease products
Drug Delivery Business News
biotech
Ocugen
eye disease
Flag link: